Mark Mulligan

Director, NYU Langone Vaccine Center · Icahn School of Medicine at Mount Sinai

Credentials: · · ·

History

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
National Institute of Allergy and Infectious Diseases · UM1
Contact PI · $22.4M · New York University School of Medicine
2020–2026
Task 12: Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae
NIH Office of the Director · N01
Contact PI · $22M · University of Alabama at Birmingham
2013–2023
System Biological Analyses of Innate and Adaptive Responses to Vaccination
National Institute of Allergy and Infectious Diseases · U19
Project lead · $11.7M · Emory University
2010–2022
Emory-CDC CTU
National Institute of Allergy and Infectious Diseases · UM1
PI · $11.7M · Emory University
2007–2020

Treating COVID-19 With Hydroxychloroquine (TEACH)
Principal investigator · Terminated · Phase 2
NYU Langone Health
2020–2021
The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Principal investigator · Completed · Phase 4
Emory University
2016
Immune Memory After Papillomavirus Vaccination
Principal investigator · Completed
Emory University
2012–2015
Yellow Fever Virus Vaccine and Immune Globulin Study
Principal investigator · Completed · Phase 1
Emory University
2006–2008